Management of Stable Behçet's Retinal Vasculitis After 2 Years of Treatment
Continue azathioprine indefinitely while initiating a gradual steroid taper to the lowest effective dose or complete discontinuation, as the current regimen has achieved disease control and azathioprine has proven long-term efficacy in preventing relapses in Behçet's posterior uveitis. 1
Rationale for Continued Azathioprine
The EULAR guidelines explicitly state that any patient with Behçet's disease and inflammatory eye disease affecting the posterior segment should be on a treatment regime that includes azathioprine and systemic corticosteroids 1. The evidence supporting this is robust:
- Azathioprine 2.5 mg/kg/day decreased hypopyon uveitis attacks (NNT = 4), stabilized visual acuity, and decreased development of new eye disease (NNT = 2) 1
- 7-year follow-up data demonstrated that the beneficial effect of azathioprine continued in the long term 1
- Recent real-world data shows that patients treated for more than 6 years had no relapses after discontinuation 2
Steroid Management Strategy
The primary goal now is aggressive steroid tapering while maintaining azathioprine:
- Corticosteroids rapidly suppress inflammation but carry significant concerns including cataracts and glaucoma with prolonged use 1
- After 2 years of oral steroids, the patient is at substantial risk for steroid-related complications
- Gradually decrease prednisone to the lowest maintenance dose that maintains remission, ideally aiming for complete discontinuation 3, 4
- Taper in small decrements (e.g., 5 mg every 2-4 weeks) while monitoring closely for disease reactivation
When to Consider Treatment Discontinuation
Based on recent evidence, azathioprine discontinuation should only be considered after 4-6 years of sustained remission, with the safest timepoint being after 6 years 2:
- Among patients who discontinued treatment after a median of 63.5 months, 30.8% experienced relapse after a median of 13 months 2
- Patients treated for more than 6 years had no relapses upon discontinuation 2
- If discontinuation is attempted prematurely (before 4 years), close monitoring is essential as relapses typically occur within 13 months 2
Monitoring During Maintenance Phase
Critical monitoring parameters include:
- Complete blood count monitoring (TPMT testing cannot substitute for CBC monitoring) 3
- Ophthalmologic examination every 3-6 months to detect subclinical reactivation
- Visual acuity assessment
- Fundoscopic examination for retinal vasculitis recurrence
- Liver function tests periodically given azathioprine hepatotoxicity risk 5
When to Escalate Therapy
If disease reactivates during steroid taper or azathioprine maintenance, escalation options include:
- First-line escalation: Add cyclosporine A (2-5 mg/kg/day) or infliximab in combination with azathioprine 1
- Alternative: Interferon-alpha with or without corticosteroids 1
- Newer options: Adalimumab has demonstrated efficacy in refractory cases 6, 7
Common Pitfalls to Avoid
- Never discontinue azathioprine while maintaining steroids alone - this reverses the appropriate hierarchy of therapy 1
- Avoid abrupt steroid withdrawal - taper gradually to prevent adrenal insufficiency and disease flare 4
- Do not stop azathioprine prematurely (before 4 years of remission) as relapse risk remains high 2
- Monitor for azathioprine toxicity - 8% of patients require discontinuation due to adverse effects, most commonly hepatotoxicity 5
The evidence strongly supports that azathioprine is the cornerstone of long-term maintenance therapy for Behçet's posterior uveitis, with proven efficacy in preventing the recurrent inflammatory attacks that lead to irreversible damage and visual loss 1, 5. Your patient's stable disease after 2 years validates this approach, and the focus should shift to minimizing steroid exposure while maintaining azathioprine protection.